Wen Chen Yeh

Chief Tech/Sci/R&D Officer at Surrozen Operating, Inc.

61 year

Health Technology

Consumer Services

Profile

Wen Chen Yeh is currently the Chief Scientific Officer at Surrozen Operating, Inc. He previously worked at Amgen, Inc. as a Scientific Executive Director from 2006 to 2016.
He also worked as a Professor at the University of Toronto.
In addition, he was the former Chief Scientific Officer at Surrozen, Inc. from 2016 to 2023.
Mr. Yeh holds a doctorate degree from The Johns Hopkins University and National Taiwan University.

Wen Chen Yeh active positions

Companies	Position	Start
Surrozen Operating, Inc. Surrozen Operating, Inc. BiotechnologyHealth Technology Surrozen Operating, Inc. operates as a biopharmaceutical company that focuses on harnessing the Wnt pathway for applications in regenerative medicine. The firm implements a surrogate Wnt platform with the potential to unlock stem cell control in an array of human tissues. The company was founded by K. Christopher Garcia, Roeland Nusse, Calvin J. Kuo, Hans Claudia and Claudia Janda in 2015 and is headquartered in South San Francisco, CA.	Chief Tech/Sci/R&D Officer	2016-04-30

All active positions of Wen Chen Yeh

Former positions of Wen Chen Yeh

Companies	Position	End
SURROZEN, INC.	Chief Tech/Sci/R&D Officer	2023-07-30
AMGEN INC.	Chief Tech/Sci/R&D Officer	2016-03-31
University of Toronto	Corporate Officer/Principal	-

See the detail of Wen Chen Yeh's experience

Training of Wen Chen Yeh

The Johns Hopkins University	Doctorate Degree
National Taiwan University	Doctorate Degree

Experiences
Positions held

Active

Inactive

Listed companies

Private companies

See the detail of Wen Chen Yeh's experience

Connections

100 +

1st degree connections

1st degree companies

Male

Female

Members of the board

Executives

See the personal network

Linked companies

Listed companies	2
AMGEN INC.	Health Technology
SURROZEN, INC.	Health Technology

Private companies	1
Surrozen Operating, Inc. Surrozen Operating, Inc. BiotechnologyHealth Technology Surrozen Operating, Inc. operates as a biopharmaceutical company that focuses on harnessing the Wnt pathway for applications in regenerative medicine. The firm implements a surrogate Wnt platform with the potential to unlock stem cell control in an array of human tissues. The company was founded by K. Christopher Garcia, Roeland Nusse, Calvin J. Kuo, Hans Claudia and Claudia Janda in 2015 and is headquartered in South San Francisco, CA.	Health Technology